Have a feature idea you'd love to see implemented?
Let us know!
RLAY Relay Therapeutics Inc
Price (delayed)
$4.64
Market cap
$776.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.61
Enterprise value
$672M
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Highlights
The equity is up by 23% since the previous quarter and by 8% year-on-year
RLAY's quick ratio is up by 17% since the previous quarter and by 12% year-on-year
The EPS has declined by 3.6% since the previous quarter but it has increased by 2.6% year-on-year
Relay Therapeutics's revenue has plunged by 72% from the previous quarter and by 61% YoY
RLAY's gross profit has dropped by 72% since the previous quarter and by 61% year-on-year
Key stats
What are the main financial stats of RLAY
Market
Valuations
Earnings
Shares outstanding
167.38M
Market cap
$776.66M
Enterprise value
$672M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
65.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.16
Revenue
$10.01M
EBIT
-$345.2M
EBITDA
-$339.69M
Free cash flow
-$282.56M
Per share
Balance sheet
Liquidity
EPS
-$2.61
Free cash flow per share
-$2.02
Book value per share
$6.27
Revenue per share
$0.07
TBVPS
$6.62
Total assets
$930.12M
Total liabilities
$91.25M
Debt
$49.82M
Equity
$838.86M
Working capital
$818.16M
Debt to equity
0.06
Current ratio
18.42
Quick ratio
17.92
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
-3,394.9%
Gross margin
100%
Net margin
-3,449.9%
Operating margin
-3,947.2%
Return on assets
-40.8%
Return on equity
-45.7%
Return on invested capital
-48.7%
Return on capital employed
-39.1%
Return on sales
-3,449.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLAY stock price
How has the Relay Therapeutics stock price performed over time
Intraday
-0.43%
1 week
-17.14%
1 month
-27.84%
1 year
-41.71%
YTD
-57.86%
QTD
-34.46%
Financial performance
How have Relay Therapeutics's revenue and profit performed over time
Revenue
$10.01M
Gross profit
$10.01M
Operating income
-$394.96M
Net income
-$345.2M
Gross margin
100%
Net margin
-3,449.9%
Relay Therapeutics's operating margin has plunged by 176% YoY
The net margin has plunged by 173% YoY
Relay Therapeutics's revenue has plunged by 72% from the previous quarter and by 61% YoY
RLAY's gross profit has dropped by 72% since the previous quarter and by 61% year-on-year
Growth
What is Relay Therapeutics's growth rate over time
Valuation
What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
65.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.16
The EPS has declined by 3.6% since the previous quarter but it has increased by 2.6% year-on-year
The P/B is 75% lower than the 5-year quarterly average of 3.0 and 47% lower than the last 4 quarters average of 1.4
The equity is up by 23% since the previous quarter and by 8% year-on-year
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 595.5 but 26% more than its last 4 quarters average of 51.8
Relay Therapeutics's revenue has plunged by 72% from the previous quarter and by 61% YoY
Efficiency
How efficient is Relay Therapeutics business performance
The return on sales has dropped by 173% year-on-year
The ROA is down by 26% YoY and by 6% QoQ
The return on invested capital has declined by 25% year-on-year and by 6% since the previous quarter
The company's return on equity fell by 20% YoY and by 4.6% QoQ
Dividends
What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLAY.
Financial health
How did Relay Therapeutics financials performed over time
Relay Therapeutics's total liabilities has decreased by 29% YoY
RLAY's total assets is up by 20% QoQ and by 2.6% YoY
The debt is 94% less than the equity
The equity is up by 23% since the previous quarter and by 8% year-on-year
Relay Therapeutics's debt to equity has decreased by 14% from the previous quarter and by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.